Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · December 19, 2022

3-Year Outcomes of P2Y12 Inhibitor Monotherapy Following DAPT After PCI

JAMA Cardiology


Additional Info

JAMA Cardiology
Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial
JAMA Cardiol 2022 Nov 01;7(11)1100-1108, KH Choi, YH Park, YB Song, TK Park, JM Lee, JH Yang, JH Choi, SH Choi, JH Oh, WJ Chun, WJ Jang, ES Im, JO Jeong, BR Cho, SK Oh, KH Yun, DK Cho, JY Lee, YY Koh, JW Bae, JW Choi, WS Lee, HJ Yoon, SU Lee, JH Cho, WG Choi, SW Rha, HC Gwon, JY Hahn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading